Nasdaq
$20.05▲ 0.05%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $632.1MShares out 31.5M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
6- 8.21After-hours26.08.22 05:37S-3Offering#●●●#●●●#●●●
Nuvectis Pharma, Inc.Bullish
Nuvectis Pharma has filed a shelf registration statement to offer up to $200 million in securities, including common stock, preferred stock, warrants, debt securities, and units. This includes an at-the-market (ATM) offering of up to $75 million through Jefferies LLC, incorporating $34.82 million in previously registered unsold securities.…more
$20.05+0.05%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 8.21After-hours26.08.22 05:318-KKey event
Nuvectis Pharma, Inc.
Nuvectis Pharma entered into an 'At-the-Market' (ATM) offering program agreement with Jefferies LLC on August 21, 2026, to sell up to $200 million of its common stock. The company terminated its prior ATM program effective July 20, 2026, and will utilize the new agreement for future capital raising.…more
$20.05+0.05%vs prev closeView filingShare - 8.6Regular26.08.07 00:19SCHEDULE 13GOwnership
Nuvectis Pharma, Inc.
Soleus Capital 관련 9개 법인 및 Guy Levy가 Nuvectis Pharma의 지분 보유 현황을 보고하기 위해 공동 공시 계약을 체결했습니다. 이번 공시는 2026년 8월 6일 자로 작성되었으며, 해당 주체들이 Schedule 13G를 공동으로 제출하기로 합의했음을 명시합니다.…more
$20.05+0.05%vs prev closeView filingShare
5 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 10.9Pre-market26.10.09 21:00#●●●#●●●
Nuvectis Pharma to Participate in the Maxim Growth Summit 2026
Nuvectis Pharma announced that its senior management will participate in the Maxim Growth Summit 2026 to discuss immunology and inflammation therapies. This is a routine investor conference appearance and does not provide immediate material impact on the stock.…more
$20.05+0.05%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 9.24Pre-market26.09.24 21:05
●●●●●●●● ●●●●● ●●●●●●
Nuvectis Pharma announced that its BRAF inhibitor NXP200 has been granted Breakthrough Therapy Designation by China's Center for Drug Evaluation. The designation recognizes the drug's potential for treating patients with BRAF V600-mutant, recurrent or progressive high-grade glioma.…more
$20.05+0.05%vs prev closeShareBenzinga - 8.21After-hours26.08.22 05:43
●●●●●●●● ●●●●● ●●●●●●
Nuvectis Pharma has filed a base prospectus with the SEC for the potential offer and sale of up to $200 million in securities. This shelf registration indicates potential future capital raising, which may lead to shareholder dilution.…more
$20.05+0.05%vs prev closeShareBenzinga
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report